Japan Airlines and SkyCell partner to meet Japanese market demand
This partnership will also see SkyCell further strengthen its presence in Japan and continue to support the temperature sensitive pharmaceutical market with its high-quality hybrid containers that have been industry accredited to have near zero spoilage rates.
Japan Airlines Cargo (JAL Cargo) and SkyCell, the manufacturer of an innovative hybrid pharmaceutical container, collaborate to meet the country's growing needs for vaccine and pharmaceutical transportation in a safe, secure and sustainable way.
SkyCell is committed to working with JAL Cargo to offer a tailor-made solution that meets the airline's growing business needs across vaccine and pharmaceutical shipments. This partnership will also see SkyCell further strengthen its presence in Japan and continue to support the temperature-sensitive pharmaceutical market with its high-quality hybrid containers that have been industry-accredited to have near-zero spoilage rates.
SkyCell’s GDP compliant hybrid containers - which maintain internal temperature stability across the pharmaceutical industry recognised temperature ranges, without the need for external intervention - are able to cover customers’ various needs.
Hidehiko Umehara, vice president, Business Promotion Department, JAL Cargo comments: “On the signing of a Master Lease Agreement, JAL and SkyCell will work in close cooperation and coordination to provide our customers with peace of mind when using SkyCell containers, which have a temperature excursion rate of less than 0.1 percent and are capable of maintaining the required temperature range at the highest levels, and do not need electric power.”
The partnership between SkyCell and JAL is the first step into a joint vision to determinedly, faithfully, and creatively increase the shipment quality of highly valuable and sensitive products.
Chiara Venuti, Business Development Director and Airline Partners, SkyCell comments, “I see this partnership with JAL as a firm commitment from SkyCell to support the Japanese pharmaceutical market. We play a key role together in delivering life-saving medicine in the safest, secure, and sustainable way to the patients in need. A great journey starts with small steps, and we look forward to working together with a common mission focused on ensuring patients get the life-saving medicines they need in a sustainable and secure way.”
